What question did this study set out to answer?

To quantify changes in calf muscular blood flow using PET following intra-arterial versus intravenous administration of prostaglandin E1 in peripheral vascular disease.

January 1, 1998Scandinavian Journal of Clinical and Laboratory Investigation

Prostaglandin E1 in peripheral vascular disease: a PET study of muscular blood flow

View Full Paper

Ask AI

Bookmark

Why the study?

Does intra-arterial or intravenous prostaglandin E1 increase muscular blood flow in patients with peripheral vascular disease?

Population

15 patients with peripheral vascular disease (PVD) and 3 healthy volunteers (total n=18)

Comparison

Prostaglandin E1 5 micrograms intra-arterially… vs Baseline measurements prior to infusion and…

Design

Cohort

Follow-up

120 minutes

Authors

SSSebastian SchellongVascular Medicine WBWolfgang BurchertHeart and Diabetes Center North Rhine-Westphalia RBR. M. BögerMedizinische Hochschule Hannover

Discussion

Member takes

Implication

Questions flow-mediated mechanism of IV PGE1 in PVD; leaves open efficacy of intra-arterial administration.

Key Points

To quantify changes in calf muscular blood flow using PET following intra-arterial versus intravenous administration of prostaglandin E1 in peripheral vascular disease.
Enrolled 15 patients with peripheral vascular disease and 3 healthy volunteers who received 5 µg intra-arterial PGE1 over 50 minutes, evaluated by 15O-water PET scans at 0, 25, and 50 minutes.
Evaluated a subgroup of 8 patients during an intravenous infusion of 40 µg PGE1 over 120 minutes with PET imaging at 0, 30, 60, and 120 minutes.
Intra-arterial PGE1 increased calf muscular blood flow by an average of 80%, with the magnitude of flow enhancement depending on femoral artery patency and showing no steal phenomenon.
Intravenous PGE1 administration resulted in unchanged calf muscular blood flow throughout the 120-minute infusion.

Structured PICO

Does intra-arterial or intravenous prostaglandin E1 increase muscular blood flow in patients with peripheral vascular disease?

Population

15 patients with peripheral vascular disease (PVD) and 3 healthy volunteers (total n=18)

Intervention

Prostaglandin E1 (PGE1) 5 micrograms intra-arterially over 50 min; a subset of 8 patients additionally received 40 micrograms PGE1 intravenously over 120 min

Comparator

Baseline measurements prior to infusion and intra-individual comparison between intra-arterial and intravenous administration

Outcome

Muscular blood flow (MBF) of the calf measured by positron emission tomography (PET) with 15O-watersurrogate

Intra-arterial PGE1 significantly increases muscular blood flow while intravenous PGE1 does not, suggesting the therapeutic efficacy of intravenous PGE1 in peripheral vascular disease is not primarily mediated by flow enhancement.

Cite This Study

Schellong et al. (1998) studied this question.

synapsesocial.com/papers/6a83f847f72f0ca72062d2e7 https://doi.org/10.1080/00365519850186689

View Full Paper

Ask AI

Bookmark

Prostaglandin E1 in peripheral vascular disease: a PET study of muscular blood flow

Discussion

Member takes

Implication

Key Points

Structured PICO

Cite This Study

Prostaglandin E1 in peripheral vascular disease: a PET study of muscular blood flow

Discussion

Member takes

Implication

Key Points

Structured PICO

Cite This Study

Also Consider

Also Consider